Back to Search
Start Over
Requirement of Hsp90 activity for I?B kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-?B activation.
- Source :
-
Oncogene . 7/8/2004, Vol. 23 Issue 31, p5378-5386. 9p. - Publication Year :
- 2004
-
Abstract
- The molecular chaperone Hsp90 affects the function and fate of a number of signaling molecules. We have investigated the Hsp90 requirement for constitutive and inducible activity of the I?B kinase (IKK) complex and of NF-?B. Inhibition by the Hsp90 ATPase inhibitors, geldanamycin (GA) and radicicol (RC), revealed that Hsp90 controls IKKs at two levels, inducibility of enzymatic activity and biogenesis, which can be discriminated by short- and long-time GA incubation, respectively. Short-time inhibition of Hsp90 resulted in impaired IKK kinase activation by TNFa, IL-1ß or phorbolester PMA. Furthermore, GA inhibited constitutive activation of IKK and NF-?B in Hodgkin's lymphoma cells. Hsp90 function was also required for trans- and autophosphorylation of transfected IKKß. GA exposure for several hours resulted in a downmodulation of IKK complex a, ß and ? subunits to various extent. Proteasome inhibition interfered with GA mediated IKK depletion and Hsp90 inhibition induced polyubiquitination of IKKa and ß during protein synthesis. In fact, GA blocked biogenesis of IKKa and IKKß but did not interfere with post-translational turnover. Together, these results define a dual requirement for Hsp90 as a regulator of NF-?B signaling by its general involvement in IKK activation and by its role in IKK homeostasis.Oncogene (2004) 23, 5378-5386. doi:10.1038/sj.onc.1207705 Published online 12 April 2004 [ABSTRACT FROM AUTHOR]
- Subjects :
- *MOLECULAR chaperones
*PROTEINS
*UBIQUITIN
*RIBOSOMES
*ORGANELLES
*TUMORS
Subjects
Details
- Language :
- English
- ISSN :
- 09509232
- Volume :
- 23
- Issue :
- 31
- Database :
- Academic Search Index
- Journal :
- Oncogene
- Publication Type :
- Academic Journal
- Accession number :
- 13696619
- Full Text :
- https://doi.org/10.1038/sj.onc.1207705